Aernoud Fiolet

207 The efficacy and safety of low-dose colchicine in patients with coronary disease 21 Supplementary Appendix Supplementary Figure S5A: Sensitivity analysis of meta-analysis of colchicine trials using a fixed-effects model for the primary and secondary composite end points Composite of myocardial infarction, stroke, or cardiovascular death Composite of myocardial infarction, stroke, or coronary revascularisation, or cardiovascular death Pooled relative risks and 95% confidence intervals for the composite of myocardial infarction, stroke, or cardiovascular death (upper panel) and for the composite of myocardial infarction, stroke, coronary revascularisation, or cardiovascular death (lower panel) in patients treated with colchicine as compared to placebo or no colchicine using a fixed effects model. Abbreviations: CI, confidence interval. GIV, generic inverse variance. Supplementary Figure S5A: Sensitivity analysis of meta-analysis of colchicine trials using a fixed- effects model for the primary and secondary composite end points Pooled relative risks and 95% confidence intervals for the composite of myocardial infarction, stroke, or cardiovascular death (upper panel) and for the composite of myocardial infarction, stroke, coronary revascularisation, or ardiovascular death (lower panel) in patients treated with colchicine as compared to placebo or no colchicine using a fixed effects model. Abbreviations: CI, confidence interval. GIV, generic inverse variance.